CDK7 inhibitors can improve the efficacy of anti-PD-1 therapy for non-small cell lung cancer (NSCLC) [28].Therefore, we further investigated the relationship between CDC25B and the TME and immune checkpoints. Here, CDC25B is linked to non-small cell lung carcinoma.